Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133092 | 0.86 | ALDH1A1 (0.48) | L3MBTL1KMT2ALMNAPCSK9NAMPT | |
| SCHEMBL26073830 | 0.81 | CA1 (0.42) | L3MBTL1KMT2AKDM4ELMNAKDM4A | |
| SCHEMBL29704350 | 0.79 | NAMPT (0.47) | L3MBTL1NAMPT | |
| SCHEMBL15932495 | 0.78 | KMT2A (0.69) | L3MBTL1KMT2AHPGDSKDM4CP2RX7 | |
| SCHEMBL13734265 | 0.78 | KMT2A (0.69) | L3MBTL1KMT2AHPGDSKDM4CP2RX7 | |
| SCHEMBL23384726 | 0.77 | KMT2A (0.46) | L3MBTL1KMT2AKDM4ELMNAKDM4A | |
| SCHEMBL31282329 | 0.77 | KDM4E (0.52) | L3MBTL1KMT2AKDM4ELMNAKDM4A | |
| SCHEMBL26926861 | 0.76 | CA12 (0.50) | PCSK9CA12CA1CA2CA9 | |
| SCHEMBL23028534 | 0.76 | DRD2 (0.48) | KDM4E | |
| SCHEMBL26926859 | 0.75 | PCSK9 (0.47) | KMT2AKDM4ELMNAKDM4APCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3888658-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-03-09 | — | — | US | disclosed |
| US-11440917-B2 | EIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| EP-3888658-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3380101-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10577378-B2 | EIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-9957277-B2 | eIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2017091585-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | L3MBTL1 403/4885KMT2A 1000/4885KDM4E 812/4885 |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | L3MBTL1 403/4885KMT2A 1000/4885KDM4E 812/4885 |
| US-11440917-B2 | EIF4A-inhibiting compounds and methods related thereto | EIF4A1, EIF4A2, EIF4A3 | L3MBTL1 403/4885KMT2A 1000/4885KDM4E 812/4885 |
| US-10577378-B2 | EIF4A-inhibiting compounds and methods related thereto | EIF4A1, EIF4A2, EIF4A3 | L3MBTL1 403/4885KMT2A 1000/4885KDM4E 812/4885 |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | L3MBTL1 403/4885KMT2A 1000/4885KDM4E 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.